DK3805268T3 - Antistof, der binder erbb-2 og erbb-3 - Google Patents

Antistof, der binder erbb-2 og erbb-3 Download PDF

Info

Publication number
DK3805268T3
DK3805268T3 DK20191815.8T DK20191815T DK3805268T3 DK 3805268 T3 DK3805268 T3 DK 3805268T3 DK 20191815 T DK20191815 T DK 20191815T DK 3805268 T3 DK3805268 T3 DK 3805268T3
Authority
DK
Denmark
Prior art keywords
erbb
antibody
binds
binds erbb
Prior art date
Application number
DK20191815.8T
Other languages
English (en)
Inventor
Cecilia Anna Wilhelmina Geuijen
Kruif Cornelis Adriaan De
Mark Throsby
Ton Logtenberg
Alexander Berthold Hendrik Bakker
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Application granted granted Critical
Publication of DK3805268T3 publication Critical patent/DK3805268T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK20191815.8T 2014-02-28 2015-02-27 Antistof, der binder erbb-2 og erbb-3 DK3805268T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14157360 2014-02-28
EP14167066 2014-05-05
EP15708907.9A EP3110849B9 (en) 2014-02-28 2015-02-27 Antibody that binds erbb-2 and erbb-3

Publications (1)

Publication Number Publication Date
DK3805268T3 true DK3805268T3 (da) 2025-01-20

Family

ID=52633560

Family Applications (2)

Application Number Title Priority Date Filing Date
DK20191815.8T DK3805268T3 (da) 2014-02-28 2015-02-27 Antistof, der binder erbb-2 og erbb-3
DK15708907.9T DK3110849T3 (da) 2014-02-28 2015-02-27 Antistof, der binder erbb-2 og erbb-3

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK15708907.9T DK3110849T3 (da) 2014-02-28 2015-02-27 Antistof, der binder erbb-2 og erbb-3

Country Status (25)

Country Link
US (5) US11279770B2 (da)
EP (4) EP3470435B1 (da)
JP (4) JP6967853B2 (da)
KR (2) KR102849905B1 (da)
CN (1) CN106459212B (da)
AU (2) AU2015223567B2 (da)
CA (1) CA2941077A1 (da)
CL (1) CL2016002156A1 (da)
CY (1) CY1123556T1 (da)
DK (2) DK3805268T3 (da)
EA (1) EA201691438A1 (da)
ES (3) ES2826774T3 (da)
FI (1) FI3805268T3 (da)
HR (2) HRP20250041T1 (da)
HU (2) HUE070182T2 (da)
IL (2) IL301147A (da)
LT (2) LT3805268T (da)
MX (1) MX383829B (da)
PL (1) PL3805268T3 (da)
RS (2) RS61129B1 (da)
SG (2) SG10201913289TA (da)
SI (2) SI3805268T1 (da)
SM (2) SMT202000642T1 (da)
WO (1) WO2015130173A1 (da)
ZA (2) ZA201605770B (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015006824A2 (pt) 2012-09-27 2017-07-04 Merus B V anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
CA2941030C (en) 2014-02-28 2025-05-13 Merus N.V. ANTIBODIES THAT BIND TO EGFR AND ERBB3
DK3805268T3 (da) * 2014-02-28 2025-01-20 Merus Nv Antistof, der binder erbb-2 og erbb-3
WO2017010874A1 (en) 2015-07-10 2017-01-19 Merus N.V. Human cd3 binding antibody
JP7296728B2 (ja) 2015-10-23 2023-06-23 メルス ナムローゼ フェンノートシャップ 癌の成長を抑制する結合分子
US10689458B2 (en) * 2015-11-30 2020-06-23 Pfizer Inc. Site specific HER2 antibody drug conjugates
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
ITUA20162242A1 (it) * 2016-04-01 2017-10-01 St Biochimico Italiano Giovanni Lorenzini Spa Un nuovo anticorpo anti-erbb2
US20200291130A1 (en) * 2017-03-31 2020-09-17 Merus N.V. Antibodies for the treatment of erbb-2/erbb-3 positive tumors
MX2019011658A (es) * 2017-03-31 2019-11-18 Merus Nv Agente que se dirige al receptor 2 del factor de crecimiento epidermico humano (erbb-2) y anticuerpo biespecifico con sitios de union a antigeno que se unen a un epitopo sobre una parte extracelular de erbb-2 y el receptor 3 del factor de crecimiento epidermico humano (erbb-3), para el tratamiento de un individuo con un tumor positivo para erbb-2, erbb-2/erbb-3.
JP7737220B2 (ja) 2017-03-31 2025-09-10 メルス ナムローゼ フェンノートシャップ ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ－２及びＥｒｂＢ３結合二重特異性抗体
EP3625264B9 (en) * 2017-05-17 2023-10-25 Merus N.V. Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
TWI887193B (zh) 2017-07-06 2025-06-21 荷蘭商米樂斯股份有限公司 藉由細胞表現之調控生物活性的抗體
RS66708B9 (sr) 2017-08-09 2025-08-29 Merus Nv Antitela koja se vezuju za egfr i cmet
WO2019185164A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Her3 antigen-binding molecules
CA3094318A1 (en) 2018-03-30 2019-10-03 Merus N.V. Multivalent antibody
SG11202105926QA (en) * 2018-12-31 2021-07-29 Merus Nv Truncated multivalent multimers
SG11202108737RA (en) * 2019-02-14 2021-09-29 Merus Nv Combinations of binding moieties that bind egfr, her2 and her3.
US20220372166A1 (en) * 2019-10-24 2022-11-24 Merus N.V. Means and methods for treating subjects with her2 and her3 positive cancer
WO2022098233A1 (en) 2020-11-04 2022-05-12 Merus N.V. Means and methods for treating subjects with erbb3 mutation positive cancer
US12551584B1 (en) 2020-12-07 2026-02-17 Actinium Pharmaceuticals, Inc. Lewis Y radioimmunotherapy for the treatment of cancer
CN117582496A (zh) 2020-12-18 2024-02-23 美勒斯公司 抗体组合物
TW202413436A (zh) 2022-08-05 2024-04-01 荷蘭商美勒斯公司 治療去勢抗性前列腺癌的手段和方法
WO2024238813A2 (en) * 2023-05-16 2024-11-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods of treating lemptomeningeal disease
WO2025188180A1 (en) 2024-03-04 2025-09-12 Merus N.V. Erbb-2 and erbb3 targeting agents for use in the treatment of malignant cells or cancers that have elevated nrg1 expression
US12414950B1 (en) 2024-05-21 2025-09-16 Telios Pharma Inc. Methods of treating indolent systemic mastocytosis
WO2026025013A2 (en) 2024-07-26 2026-01-29 Pfizer Inc. Combination therapy using cdk4 inhibitors for cancer treatments

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
FI884924A7 (fi) 1987-10-28 1989-04-29 Oncogen Yhdistelmä-DNA-tekniikalla tuotettuja ihmisimmunoglobuliineja
US5151504A (en) 1989-11-17 1992-09-29 E. R. Squibb & Sons, Inc. Method for purification of monoclonal antibodies
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
NZ243558A (en) 1991-07-15 1994-06-27 Wellcome Found Recombinant primate antibodies and their production
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
ES2378272T3 (es) 1999-04-15 2012-04-10 Crucell Holland B.V. Producción de proteína recombinante en una célula humana
DE29915950U1 (de) 1999-09-10 1999-12-30 CMW Automation GmbH, 65594 Runkel Vorrichtung zum Elektrolytbefüllen der Zellen eines Akkumulators
US20070111201A1 (en) 2001-04-30 2007-05-17 Benjamin Doranz Reverse transfection of cell arrays for structural and functional analyses of proteins
DE60237048D1 (de) 2001-07-04 2010-08-26 Chromagenics Bv DNS-Sequenzen mit Anti-Repressor-Aktivität
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
WO2003107218A1 (ja) 2002-05-31 2003-12-24 セレスター・レキシコ・サイエンシズ株式会社 相互作用予測装置
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
EA013225B1 (ru) 2003-01-07 2010-04-30 Симфоген А/С Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток
NZ543635A (en) 2003-06-25 2008-05-30 Crucell Holland Bv Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML
AU2005249396B2 (en) 2004-05-05 2011-10-20 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
SG188175A1 (en) 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
US8290739B2 (en) 2006-10-20 2012-10-16 Amfit, Inc. Method for determining relative mobility of regions of an object
AU2007353412A1 (en) 2006-11-21 2008-11-20 Fox Chase Cancer Center Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
NZ579644A (en) 2007-02-16 2012-05-25 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
EP2626372B1 (en) 2007-03-29 2018-03-21 Genmab A/S Bispecific antibodies and methods for production thereof
PL2155788T3 (pl) 2007-04-03 2013-02-28 Amgen Res Munich Gmbh Swoiste międzygatunkowe bispecyficzne czynniki wiążące
US7705103B2 (en) 2007-06-22 2010-04-27 3M Innovative Properties Company Polydiorganosiloxane polyoxamide copolymers
ES2694018T3 (es) 2007-07-02 2018-12-17 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para el tratamiento y el diagnóstico del cáncer
US8536310B2 (en) 2007-10-17 2013-09-17 Arca Biopharma, Inc. Antibodies to CLL-1
WO2009086197A1 (en) 2007-12-20 2009-07-09 Monogram Biosciences, Inc. Her-2 diagnostic methods
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
CA2715043C (en) 2008-02-05 2021-02-16 Zymeworks Inc. Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics
JP5639039B2 (ja) * 2008-04-11 2014-12-10 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
EP3456191A1 (en) 2008-06-27 2019-03-20 Merus N.V. Antibody producing non-human mammals
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
BRPI1007321A2 (en) 2009-01-15 2018-07-10 Laboratory Corporation Of America Holdings methods for measuring and / or quantifying the presence and / or amount of her-3 or her-3 in a complex in a patient sample, and to determine if an individual with cancer is likely to respond to treatment with a targeted therapy. and antibody.
CN104262483A (zh) 2009-01-26 2015-01-07 根马布股份公司 用于生成抗体混合物的方法
KR20150036824A (ko) 2009-03-20 2015-04-07 제넨테크, 인크. 이중특이적 항-ｈｅｒ 항체
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP2496598B1 (en) * 2009-11-04 2017-08-02 Affibody AB Her3 binding polypeptides
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
US20130185821A1 (en) * 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
WO2012023053A2 (en) 2010-08-16 2012-02-23 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
ME02637B (me) 2010-08-20 2017-06-20 Novartis Ag Antitela za receptor 3 faktora rasta epiderma (her3)
TW201302793A (zh) * 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
CA2828099A1 (en) 2011-02-24 2012-08-30 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
US20140134170A1 (en) 2011-03-11 2014-05-15 Merrimack Pharmaceuticals, Inc. Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
EP2815765A1 (en) * 2011-03-15 2014-12-24 Merrimack Pharmaceuticals, Inc. Overcoming resistance to ERBB pathway inhibitors
JP2014511836A (ja) 2011-03-25 2014-05-19 グレンマーク ファーマシューティカルズ， エセ．アー． ヘテロ二量体免疫グロブリン
NO2707391T3 (da) * 2011-05-13 2018-04-07
WO2012176779A1 (ja) * 2011-06-20 2012-12-27 協和発酵キリン株式会社 抗ｅｒｂＢ３抗体
US9567827B2 (en) 2013-07-15 2017-02-14 Downhole Technology, Llc Downhole tool and method of use
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
WO2013048883A2 (en) 2011-09-30 2013-04-04 Regeneron Pharmaceuticals, Inc. Anti-erbb3 antibodies and uses thereof
CN108424456B (zh) * 2011-11-23 2022-04-26 医学免疫有限责任公司 特异于her3的结合分子及其用途
CN108341873B (zh) * 2011-12-05 2022-03-25 诺华股份有限公司 表皮生长因子受体3(her3)的抗体
EP2788381A2 (en) 2011-12-05 2014-10-15 Novartis AG Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3
CN102448183A (zh) 2012-01-18 2012-05-09 大唐移动通信设备有限公司 一种Uu接口重配置方法及设备
EP2823270B1 (en) 2012-03-09 2022-05-04 Promega Corporation pH SENSORS
WO2013148315A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
BR112015006824A2 (pt) 2012-09-27 2017-07-04 Merus B V anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
EP2906591A1 (en) * 2012-10-15 2015-08-19 Universität Zürich Bispecific her2 ligands for cancer therapy
JP2016512533A (ja) 2013-03-14 2016-04-28 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｍｅｔ結合剤およびその使用
CA2908515A1 (en) 2013-04-05 2014-10-09 Laboratory Corporation Of America Holdings Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation
US10239951B2 (en) 2013-05-08 2019-03-26 Zymeworks Inc. Bispecific HER2 and HER3 antigen binding constructs
US11229711B2 (en) 2013-06-06 2022-01-25 Magenta Therapeutics, Inc. Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
US9551208B2 (en) 2013-08-26 2017-01-24 Halliburton Energy Services, Inc. Identifying uncertainty associated with a stimulated reservoir volume (SRV) calculation
WO2015066543A1 (en) * 2013-11-01 2015-05-07 Board Of Regents, The University Of Texas System Targeting her2 and her3 with bispecific antibodies in cancerous cells
DK3805268T3 (da) 2014-02-28 2025-01-20 Merus Nv Antistof, der binder erbb-2 og erbb-3
CA2941030C (en) * 2014-02-28 2025-05-13 Merus N.V. ANTIBODIES THAT BIND TO EGFR AND ERBB3
US10813952B2 (en) 2014-11-14 2020-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors
JP7737220B2 (ja) * 2017-03-31 2025-09-10 メルス ナムローゼ フェンノートシャップ ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ－２及びＥｒｂＢ３結合二重特異性抗体

Also Published As

Publication number Publication date
EA201691438A1 (ru) 2017-04-28
WO2015130173A1 (en) 2015-09-03
EP3470435A1 (en) 2019-04-17
KR102849905B1 (ko) 2025-08-26
SMT202500020T1 (it) 2025-03-12
IL247520B2 (en) 2023-08-01
RS61129B1 (sr) 2020-12-31
US11279770B2 (en) 2022-03-22
JP2022071071A (ja) 2022-05-13
MX383829B (es) 2025-03-14
ZA202105920B (en) 2023-05-31
SG11201607104RA (en) 2016-09-29
EP3805268A1 (en) 2021-04-14
ES2833599T3 (es) 2021-06-15
CY1123556T1 (el) 2022-03-24
HUE052506T2 (hu) 2021-05-28
JP2024079823A (ja) 2024-06-11
SG10201913289TA (en) 2020-02-27
RS66392B1 (sr) 2025-02-28
ES3006007T3 (en) 2025-03-17
JP2017507944A (ja) 2017-03-23
KR20160145560A (ko) 2016-12-20
CN106459212A (zh) 2017-02-22
US20220348683A1 (en) 2022-11-03
JP6967853B2 (ja) 2021-11-17
IL247520B1 (en) 2023-04-01
EP3110849A1 (en) 2017-01-04
ZA201605770B (en) 2022-04-28
SI3805268T1 (sl) 2025-03-31
US20230242669A1 (en) 2023-08-03
MX2016011155A (es) 2017-02-22
KR20240042540A (ko) 2024-04-02
US20170037145A1 (en) 2017-02-09
EP3470435B1 (en) 2020-08-05
EP3110849B9 (en) 2021-04-07
PL3805268T3 (pl) 2025-03-31
EP4644425A1 (en) 2025-11-05
SI3110849T1 (sl) 2021-01-29
NZ724012A (en) 2021-09-24
DK3110849T3 (da) 2020-11-23
US20240158532A1 (en) 2024-05-16
IL301147A (en) 2023-05-01
IL247520A0 (en) 2016-11-30
US12139548B2 (en) 2024-11-12
LT3110849T (lt) 2020-12-10
EP3110849B1 (en) 2020-08-26
CL2016002156A1 (es) 2017-06-23
JP7358256B2 (ja) 2023-10-10
FI3805268T3 (fi) 2025-01-07
CA2941077A1 (en) 2015-09-03
AU2015223567A1 (en) 2016-09-01
HUE070182T2 (hu) 2025-05-28
JP2020097590A (ja) 2020-06-25
AU2020286212A1 (en) 2021-01-07
SMT202000642T1 (it) 2021-01-05
LT3805268T (lt) 2025-01-27
AU2015223567B2 (en) 2020-09-10
HRP20201837T1 (hr) 2021-04-02
HRP20250041T1 (hr) 2025-03-14
CN106459212B (zh) 2021-07-13
ES2826774T3 (es) 2021-05-19
EP3805268B1 (en) 2024-12-04
US20240158531A1 (en) 2024-05-16

Similar Documents

Publication Publication Date Title
ZA202105920B (en) Antibody that binds erbb-2 and erbb-3
IL304772A (en) Antibodies, uses and methods
IL264654B1 (en) Anti-tigit antibodies, anti-pvrig antibodies and their combinations
DK3370768T3 (da) Antistoffer som specifikt binder pd-1 og anvendelser deraf
DK3223845T3 (da) Heterodimere antistoffer, der binder cd3 og cd20
DK3922645T3 (da) Anti-pro/latent-myostatin-antistoffer og anvendelse heraf
DK3333191T3 (da) Anti-C10ORF54-antistoffer og anvendelser deraf
DK3126388T3 (da) Anti-EGFRvIII-antistoffer og anvendelser deraf
DK3242892T3 (da) Modificerede april-bindende antistoffer
DK3169706T3 (da) Antistoffer, der binder axl
PL3101032T3 (pl) Koniugat przeciwciało anty-HER2-lek
HUE048111T2 (hu) Anti-CEACAM6 ellenanyagok és alkalmazásuk
DK3169703T3 (da) Kimær antigenreceptor og anvendelse deraf
PL3311170T3 (pl) Przeciwciało
PL3215530T3 (pl) Ulepszone przeciwciała anty-il-6
IL252430A0 (en) Antibodies, uses and methods
DK3110447T3 (da) Anti-EGFR-antistof og anvendelser heraf
IL257368A (en) Antibody
DK3368567T3 (da) Humaniseret anti-dkk2-antistof og anvendelser heraf
DK3239177T3 (da) Nyt egfrviii antistof og sammensætning omfattende samme
DK3283571T3 (da) Klart bindemiddel og anvendelser deraf
DK3233912T3 (da) Antistoffer, der binder human c6, og anvendelser deraf
PT3805268T (pt) Anticorpo que liga erbb-2 e erbb-3
TH1501005181A (th) แอนติบอดีที่ยึดเกาะ il-23